Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 14/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202518 | 0.87 | SMYD3 (0.44) | THRBSMYD3 | |
| SCHEMBL18651739 | 0.87 | SMYD3 (0.33) | SMYD3 | |
| SCHEMBL13854233 | 0.86 | ALDH1A1 (0.37) | SMYD3 | |
| SCHEMBL13854234 | 0.84 | HSD17B10 (0.34) | SMYD3 | |
| SCHEMBL13854243 | 0.82 | THRB (0.36) | THRBTHRACES1 | |
| SCHEMBL13854238 | 0.79 | EPHX2 (0.46) | SMYD3CES1 | |
| SCHEMBL13854244 | 0.77 | THRB (0.33) | THRBCES1 | |
| SCHEMBL14498106 | 0.74 | THRB (0.33) | THRBCES1 | |
| SCHEMBL4197975 | 0.73 | SMYD3 (0.46) | SMYD3 | |
| SCHEMBL14497591 | 0.72 | EPHX2 (0.36) | SMYD3CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130165-A1 | MIF Inhibitors | MIF, MMP12, IL4 | THRB 3310/4885SMYD3 4031/4885THRA 4159/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | THRB 2300/4885SMYD3 3217/4885THRA 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.